Tema肿瘤学主动型ETF CANC 深 沪
等待开盘 02-03 09:30:00 美东时间
36.47
+0.710
+1.99%
华盛通- 最 高36.47
- 今 开35.71
- 成交量 4.09万股
- 最 低 35.71
- 昨 收 35.76
- 总市值 1.04亿
- 52周最高 37.51
- 市盈率 静 --
- 换手率 1.43%
- 52周最低 20.0759
- 委 比 0.00%
- 总股本 285.00万
- 历史最高 37.51
- 量 比 0.88
- 振 幅 2.13%
- 历史最低 20.0759
- 每 手 1
- 风险率 4.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-IHH Healthcare Made A Strategic Investment In U.S.-Based TibaRay
BRIEF-IHH Healthcare Made A Strategic Investment In U.S.-Based TibaRay Jan 29 (Reuters) - IHH Healthcare Bhd IHHH.KL : MADE A STRATEGIC INVESTMENT IN U.S.-BASED TIBARAY INVESTMENT IN NEXT-GENERATION RADIOTHERAPY AIMS TO MAKE CANCER TREATMENT MORE EFFICIENT, OTHERS Further company coverage: IHHH.KL
01-29 14:48
BRIEF-Rhythm Biosciences Secures Strategic Us Partnership With Cancer IQ
BRIEF-Rhythm Biosciences Secures Strategic Us Partnership With Cancer IQ Jan 28 (Reuters) - Rhythm Biosciences Ltd RHY.AX : SECURES STRATEGIC US PARTNERSHIP WITH CANCER IQ Further company coverage: RHY.AX (( Reuters.Briefs@thomsonreuters.com ;))
01-28 09:37
BRIEF-New England Journal Of Medicine Publishes Phase 3 Ascent-04/Keynote-D19 Results
BRIEF-New England Journal Of Medicine Publishes Phase 3 Ascent-04/Keynote-D19 Results Jan 21 (Reuters) - Gilead Sciences Inc GILD.O : NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES PHASE 3 ASCENT-04/KEYNOTE-D19 RESULTS SUPPORTING TRODELVY® PLUS KEYTRUDA® AS A POTENTIAL NEW STANDARD OF CARE IN FIRST-LINE
01-22 06:18
BRIEF-Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers
BRIEF-Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers Jan 21 (Reuters) - Actuate Therapeutics Inc ACTU.O : ACTUATE THERAPEUTICS ANNOUNCES PLANS TO EXPAND CLINICAL PIPELINE, ADVANCING ELRAGLUSIB TABL
01-21 21:46
Tema Oncology ETF declares $0.0196 dividend
Tema Oncology ETF (CANC) declares $0.0196/share annual dividend. Payable Dec. 11; for shareholders of record Dec. 10; ex-div Dec. 10. See CANC Dividend Scorecard, Yield Chart, & Dividend Growth. More ...
2025-12-10 22:30
